lexi
IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1122 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »  Article in PDF (269 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

 
In This Article
 » Acknowledgments
 »  References
 »  Article Tables

 Article Access Statistics
    Viewed5476    
    Printed114    
    Emailed2    
    PDF Downloaded162    
    Comments [Add]    
    Cited by others 10    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2013  |  Volume : 45  |  Issue : 4  |  Page : 417-418
 

Effects of Withania somnifera in patients of schizophrenia: A randomized, double blind, placebo controlled pilot trial study


1 Department of Pharmacology, Government Medical College, Nagpur, India
2 Department of Pharmacology, VCSG Govt. Medical Science and Research Institute, Srikot, Garhwal, Uttarakhand, India
3 Ayurvedic Practitioner, Nagpur, India

Date of Web Publication15-Jul-2013

Correspondence Address:
Smita D Sontakke
Department of Pharmacology, Government Medical College, Nagpur
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.115012

Rights and Permissions



How to cite this article:
Agnihotri AP, Sontakke SD, Thawani VR, Saoji A, Goswami VS. Effects of Withania somnifera in patients of schizophrenia: A randomized, double blind, placebo controlled pilot trial study. Indian J Pharmacol 2013;45:417-8

How to cite this URL:
Agnihotri AP, Sontakke SD, Thawani VR, Saoji A, Goswami VS. Effects of Withania somnifera in patients of schizophrenia: A randomized, double blind, placebo controlled pilot trial study. Indian J Pharmacol [serial online] 2013 [cited 2022 May 21];45:417-8. Available from: https://www.ijp-online.com/text.asp?2013/45/4/417/115012


Sir,

Second-generation antipsychotics are known to be associated with higher incidence of metabolic syndrome (MS). [1] Withania somnifera (WS) is a herb in the Ayurvedic system of medicine and has been found to decrease blood glucose comparable to an oral hypoglycemic. [2] A significant increase in urine sodium and urine volume, and a significant decrease in serum cholesterol, triglycerides, low-density lipoproteins, and very low density lipoproteins have been reported with use of WS, indicating its potential use as a diuretic and hypocholesterolemic agent. [3] Hence, a trial was planned with an objective to study its metabolic effects in schizophrenia patients receiving antipsychotic therapy and suffering from MS.

A randomized, double blind, placebo controlled, clinical trial was conducted in psychiatry OPD of a tertiary care teaching hospital after approval of Institutional Ethics Committee. Schizophrenia patients receiving second-generation antipsychotics for 6 months or more, having serum triglycerides more than 150 mg/dl, high-density lipoprotein (HDL) cholesterol less than 40 mg/dl in men and less than 50 mg/dl in women, fasting blood glucose(FBG) level more than 100 mg/dl, aged above 18 years were included. Patients suffering from other psychiatric/systemic illnesses, receiving concurrent medicines, pregnant/lactating women were excluded. Patients were briefed about the study and written informed consent was obtained from those willing to participate. Baseline investigations (routine hematological, liver and kidney function tests, FBG, serum triglycerides, HDL cholesterol) were performed. Baseline blood pressure and weight were recorded.

Selected patients were randomly allocated by SAS systems of Windows to two groups of 15 each, to receive either Withania somniferaextract (WSE) [Cap Strelaxin, manufactured by M/s Pharmanza Herbal Pvt. Ltd. Gujarat, India] containing 400 mg of WSE per capsule or matching placebo given in a dose of one capsule thrice daily for 1 month. Patients were informed to report in the case of any adverse effect. After 1 month of treatment, FBG, serum triglycerides, and HDL cholesterol were repeated. Comparison of baseline and post-treatment values was done by paired 't' test and unpaired 't' test was used to compare results of the two groups. Data was analyzed by using Graph pad Prism version 4.03 software. P<0.05 was considered statistically significant.

Out of 30 patients, 3 from WS and 2 from the placebo group were lost to follow-up. No change in body weight and blood pressure was observed after 1 month of treatment in both groups.

Demographic characteristics were comparable in the two treatment groups. No change in all three biochemical parameters was found after 1 month of treatment in the placebo group [Table 1]. However, a statistically significant (P<0.05) reduction in serum triglycerides and FBG was observed after 1 month of WS treatment compared to the placebo group. Patients of both groups reported feeling of isolation and depression.
Table 1: Comparison of serum triglycerides, HDL cholesterol, and fasting blood glucose in patients treated with Withania somnifera

Click here to view


Hypolipidemic and hypoglycemic actions of WS have been reported in experimental studies [3] and in clinical trials after 1 month of treatment. [2] A clinical trial in patients of noninsulin-dependent diabetes mellitus with hypercholesterolemia reported a decrease in blood glucose with WS being comparable to that of an oral hypoglycemic. [2] Bhattacharya et al. have suggested that WS has an antioxidant effect which may be responsible for its diverse pharmacological properties. [4]

Hypoglycemic and hypolipidaemic effects of WS observed in this trial are significant and deserve to be explored further. The results of this trial, if confirmed through large clinical trials, will certainly aid the therapeutics not only for patients having drug-induced MS but also for those having MS due to other causes. Symptoms like feeling of isolation and depression reported in this trial are known to occur during the natural course of schizophrenia. No ADR attributable to WSE was reported. Further studies are required to establish the efficacy and safety of WS for patients suffering from MS.


 » Acknowledgments Top


We thank the Indian Council of Medical Research for providing financial support for this trial. We are grateful to Dr. Lal Hingorani Pharmanza, Gujrat (India) for providing trial medicines.

 
 » References Top

1.Jacob R, Chowdhury AN. Metabolic comorbidity in schizophrenia. Indian J Med Sci 2008;62:23-31.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.Andallu B, Radhika B. Hypoglycemic, diuretic and hypocholesterolemic effect of Winter cherry (Withania somnifera, Dunal) root. Indian J Exp Biol 2000;38:607-9.  Back to cited text no. 2
[PUBMED]    
3.Visavadiya NP, Narasimhacharya AV. Hypocholesteromic and antioxidant effects of Withania somnifera (Dunal) in hypercholesteremic rats. Phytomedicine 2007;14:136-42.  Back to cited text no. 3
[PUBMED]    
4.Bhattacharya SK, Satyan KS, Chakrabarti A. Effect of Trasina, an Ayurvedic herbal formulation on pancreatic islet superoxide dismutase activity in hyperglycemic rats. Indian J Exp Biol 1999;35:297-9.  Back to cited text no. 4
    



 
 
    Tables

  [Table 1]

This article has been cited by
1 Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol
Arvind Chopra, Preeti Chavan-Gautam, Girish Tillu, Manjit Saluja, Swapnil Borse, Sanjeev Sarmukaddam, Susmita Chaudhuri, BCS Rao, Babita Yadav, Narayanam Srikanth, Bhushan Patwardhan
Frontiers in Medicine. 2022; 9
[Pubmed] | [DOI]
2 Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries
Masuma Pervin Mishu, Eleonora Uphoff, Faiza Aslam, Sharad Philip, Judy Wright, Nilesh Tirbhowan, Ramzi A Ajjan, Zunayed Al Azdi, Brendon Stubbs, Rachel Churchill, Najma Siddiqi
Cochrane Database of Systematic Reviews. 2021; 2021(2)
[Pubmed] | [DOI]
3 Ashwagandha (Withania somnifera) for the treatment and enhancement of mental and physical conditions: A systematic review of human trials
Adrian L. Lopresti, Stephen J. Smith
Journal of Herbal Medicine. 2021; 28: 100434
[Pubmed] | [DOI]
4 Withania somnifera (L.) Dunal - Modern perspectives of an ancient Rasayana from Ayurveda
Pulok K. Mukherjee, Subhadip Banerjee, Sayan Biswas, Bhaskar Das, Amit Kar, C.K. Katiyar
Journal of Ethnopharmacology. 2021; 264: 113157
[Pubmed] | [DOI]
5 Use of Dietary Supplements in Living Kidney Donors: A Critical Review
Amanda K. Leonberg-Yoo, David Johnson, Nicole Persun, Jehan Bahrainwala, Peter P. Reese, Ali Naji, Jennifer Trofe-Clark
American Journal of Kidney Diseases. 2020; 76(6): 851
[Pubmed] | [DOI]
6 RNA-seq reveals novel mechanistic targets of withaferin A in prostate cancer cells
Su-Hyeong Kim, Eun-Ryeong Hahm, Krishna B Singh, Sruti Shiva, Jacob Stewart-Ornstein, Shivendra V Singh
Carcinogenesis. 2020; 41(6): 778
[Pubmed] | [DOI]
7 A Comprehensive Review and Perspective on Anticancer Mechanisms of Withaferin A in Breast Cancer
Eun-Ryeong Hahm, Su-Hyeong Kim, Krishna B. Singh, Kamayani Singh, Shivendra V. Singh
Cancer Prevention Research. 2020; 13(9): 721
[Pubmed] | [DOI]
8 Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human ailments
Neeraj Tandon, Satyapal Singh Yadav
Journal of Ethnopharmacology. 2020; 255: 112768
[Pubmed] | [DOI]
9 Withania somnifera (Indian ginseng) in diabetes mellitus: A systematic review and meta-analysis of scientific evidence from experimental research to clinical application
Sharanbasappa Durg, Sachin Bavage, Shivakumar B. Shivaram
Phytotherapy Research. 2020; 34(5): 1041
[Pubmed] | [DOI]
10 Antitumor Immunity and Dietary Compounds
Annalise Smith,Samita Andreansky
Medical Sciences. 2013; 2(1): 1
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow